Designing vaccines to neutralize effective toxin delivery by enterotoxigenic Escherichia coli by Fleckenstein, James M. & Sheikh, Alaullah




Designing vaccines to neutralize effective toxin
delivery by enterotoxigenic Escherichia coli
James M. Fleckenstein
Washington University School of Medicine in St. Louis
Alaullah Sheikh
Washington University School of Medicine in St. Louis
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Fleckenstein, James M. and Sheikh, Alaullah, ,"Designing vaccines to neutralize effective toxin delivery by enterotoxigenic Escherichia
coli." Toxins.6,6. 1799-1812. (2014).
http://digitalcommons.wustl.edu/open_access_pubs/2986






Designing Vaccines to Neutralize Effective Toxin Delivery by 
Enterotoxigenic Escherichia coli 
James M. Fleckenstein 1,2,3,* and Alaullah Sheikh 2 
1 Division of Infectious Diseases, Washington University School of Medicine, 660 South Euclid 
Avenue; Saint Louis, MO 63110, USA 
2 Molecular Microbiology and Microbiobial Pathogenesis Program, Division of Biology and 
Biomedical Sciences, Washington University School of Medicine, Campus Box 8051, 660 South 
Euclid Avenue; Saint Louis, MO 63110, USA; E-Mail: asheikh@wustl.edu 
3 Veterans Affairs Medical Center, Saint Louis, MO 63106, USA 
* Author to whom correspondence should be addressed; E-Mail: jflecken@wustl.edu;  
Tel.: +1-314-362-9218; Fax: +1-314-362-9230. 
Received: 7 March 2014; in revised form: 23 April 2014 / Accepted: 15 May 2014 /  
Published: 10 June 2014
 
Abstract: Enterotoxigenic Escherichia coli (ETEC) are a leading cause of diarrheal illness 
in developing countries. Despite the discovery of these pathogens as a cause of cholera-like 
diarrhea over 40 years ago, and decades of vaccine development effort, there remains no 
broadly protective ETEC vaccine. The discovery of new virulence proteins and an 
improved appreciation of the complexity of the molecular events required for effective 
toxin delivery may provide additional avenues to pursue in development of an effective 
vaccine to prevent severe diarrhea caused by these important pathogens. 
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The enterotoxigenic Escherichia coli (ETEC) are a leading cause of diarrheal illness in developing 
countries where these diverse pathogens account for millions of infections and hundreds of  
thousands of deaths each year [1], particularly in young children under two years of age [2,3]. ETEC 
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produce a number of different enterotoxins which either individually or collectively cause net  
secretion of water into the lumen of the small intestine, resulting in characteristic voluminous watery 
diarrhea. Illness that accompanies ETEC infection can range from mild self-limited diarrhea to  
severe rapid fluid losses clinically indistinguishable from cholera. 
While it may be particularly important to prevent cholera-like disease to avoid deaths from diarrheal 
illness, the association of ETEC with delayed growth [4] and malnutrition [5,6] in developing 
countries could imply that an effective vaccine would have a more far-reaching impact on the health of 
young children at risk for these ubiquitous infections. Unfortunately, despite the global importance of 
these infections, and considerable investigation following the initial discovery of these organisms more  
than 40 years ago, there currently is no licensed broadly protective ETEC vaccine [7]. 
Understanding the precise molecular events involved in delivery of ETEC toxins could provide key 
insights that inform development of more effective vaccines. The recent identification of novel 
virulence factors required for optimal interaction of these organisms with target epithelial cells 
suggests that essential elements of toxin delivery are still being defined. Dissection of the details of 
ETEC pathogen-host interactions has provided additional molecules that can be targeted in new 
iterations of ETEC vaccines.  
2. ETEC Enterotoxins 
The ETEC pathotype of diarrheagenic E. coli is defined by genes encoding one of three toxins:  
the heat-labile toxin (LT), and the heat-stable toxins ST-Ia (ST-P), or ST-Ib (ST-H). ETEC strains may 
encode any or all of these toxins each of which has been associated with severe diarrheal illness. 
2.1. Heat-Labile Toxin (LT) 
LT is an AB5 heterohexameric molecule that shares approximately 85% amino acid identity with 
cholera toxin (CT). The pentameric B subunit binds to GM-1 gangliosides on the surface of intestinal 
epithelial cells triggering the internalization of the catalytically active A subunit. Within the cell,  
the A subunit allosterically activates ADP-ribosylating factors (ARFs) which affect the ADP 
ribosylation of the intracellular guanine nucleotide binding protein, Gsα, abolishing its GTPase 
activity, and leading to constitutive activation of adenylate cyclase which increases intracellular 
cAMP. The resulting intracellular increases in cAMP then activate protein kinase A, in turn 
phosphorylating the cystic fibrosis transmembrane regulator (CFTR) [8]. It is the ensuing efflux  
of chloride through this channel accompanied by inhibition of Na+ absorption through Na/H ion 
exchangers (NHE3) [9] that results in the intraluminal transfer of salt and water that lead to  
profound diarrhea and rapid dehydration. 
2.2. Heat-Stable Toxins (ST) 
ST-Ia and ST-Ib are small (18–19 amino acid) peptides with multiple cysteine residues. These 
molecules are structurally similar molecular mimics of two native eukaryotic gastrointestinal peptides, 
guanylin and uroguanylin. Both ST-I molecules and their native homologues engage guanylyl  
cyclase C in the epithelial cell membrane and activate the enzyme activity leading to intracellular 
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increases in cGMP. This cyclic nucleotide also activates protein kinases that phosphorylate and 
activate CFTR [10,11], resulting in toxin-induced intestinal fluid losses similar to LT. 
3. Strategies to Neutralize Toxin Delivery 
3.1. Essential Requirements for an Effective Vaccine 
Although ETEC are defined as a pathotype by the production of the enterotoxins described above, 
the pathogenesis of ETEC can best be summarized as the total compilation of virulence features 
required for effective delivery of these toxins to their cognate receptors on the epithelial surface  
(Table 1). In essence then, effective ETEC vaccines need to prevent these pathogens from successfully 
delivering their toxin payload to the appropriate receptor either by direct neutralization of the 
enterotoxins and/or indirectly by engaging virulence factors that are required elements of toxin delivery. 
Table 1. Virulence features required for optimal Enterotoxigenic Escherichia coli (ETEC) toxin delivery. 
Virulence feature Biology/structure Function(s) Reference(s) 
colonization factors 
plasmid-encoded fimbrial, fibrillar structures 
belonging to chaperone-usher-pilus (CUP) family 
(length ~1 µm) 
structural adhesin [12] 
type 1 fimbriae 
chromosomally-encoded CUP fimbrial structures 
(length ~1 µm) 
structural adhesin [13,14] 
flagella 
peritrichous arrangement; 
(length ~10 µm) 
motility, adhesion [15] 








YghJ secreted T2SS effector; metalloprotease mucin degradation [18] 
3.2. Direct Toxin Neutralization 
3.2.1. Anti-LT Toxoids 
Heat-labile toxin is a principal target for ETEC vaccine development. Because of inherent 
immunogenicity and substantial adjuvant activity [19] some form of LT is incorporated in most  
ETEC vaccines currently in clinical trials [20–23]. Moreover, epidemiologic studies as well as  
earlier vaccine studies have suggested that previous exposure to LT [24] or CT [25,26] can afford 
protection against subsequent infection with LT-producing ETEC. Interestingly, recent efforts to 
develop an LT-based ETEC vaccine patch were met with partial success in that they were protective 
against strains that only produced this toxin [27]. Collectively, these data support the use of LT  
and related molecules in ETEC vaccines; therefore, understanding the correct approach to  
development of LT toxoids appears to be integral to vaccine development. 
Theoretically, neutralization of either the A or B subunit of LT could provide protection, either by 
engaging the active toxin moiety or by preventing binding of the toxin to its receptor, respectively. 
Indeed, experiments have demonstrated that these effects appear to be additive in preventing LT 
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holotoxin-induced cAMP activation in target epithelial cells [16]. Mutant forms of LT have  
therefore been constructed [28] which are devoid of enterotoxic activity [29] but which retain the 
ability to stimulate antibodies against both subunits, as well as their respective contributions to  
LT-adjuvant activity [30]. 
While LT antitoxin immunity may afford some degree of protection against strains that produce 
only this toxin, the majority of strains produce either ST or both toxins, with approximately  
half of all strains producing only ST [31], where LT-toxoids would presumably offer no benefit [32]. 
Therefore, additional investigation will be required to determine the optimal complement of antigens 
that might be combined with LT-toxoids to extend coverage and enhance the overall efficacy. 
3.2.2. Anti-ST Toxoids 
ST toxoids have faced a number of substantive challenges [33], including the small size and poor 
immunogenicity of these molecules, their inherent toxicity, and similarity to endogenous peptides.  
In addition, earlier studies suggested that high titers of antibody might be needed at the mucosal 
surface to neutralize activity of these toxins [34]. The ideal vaccine construct(s) would then be  
devoid of toxic activity, engender neutralizing immune responses to both ST-h and ST-p, and avoid 
cross-reactions to human uroguanylin, or guanylin.  
Studies to date have demonstrated that it is possible, either by chemical conjugation of ST  
peptides to carrier molecules [35–39], or by genetic construction of ST-fusion proteins [40–45], to 
induce antibodies to ST. Earlier experiments with a modified ST molecule conjugated to heat-labile 
toxin B subunit (LT-B) provided compelling evidence that it is possible to generate neutralizing 
antibodies against ST in humans. Following oral administration of the ST-LT-B conjugate, human 
volunteers mounted neutralizing serum and intestinal antibodies against ST [46]. 
Most recent attempts to generate ST antibodies have relied on genetic fusions of ST to other 
molecules with potent adjuvant activity such as LT. This approach has the distinct advantage of 
being relatively simple with respect to design and production of potential fusions permitting 
preclinical testing on a variety of constructs, but cannot achieve the high hapten: carrier ratios 
anticipated with chemical conjugation methods [33]. Nevertheless, there is compelling evidence in 
pigs, a natural model of ETEC infections, that this approach has merit. Fusion of ST-II to a mutant 
version of LT resulted in antibodies to both partners and was protective against porcine diarrheal 
illness in young piglets [43]. Based on these results, a similar approach is being taken with ST-I 
peptides relevant for humans [43,47]. 
A concerted effort to optimize the approach to formulating either conjugate or genetic fusions is 
ongoing [33,48,49]. It is likely however, that to achieve the broad-based sustained protection required 
for a vaccine to find utility in developing countries, additional antigens and a thorough understanding 
of pathogenesis will determine the best strategy to mitigate toxin delivery.  
3.3. Classical Colonization Factor-Based Approaches 
Along with attempts to develop LT-based toxoids, plasmid-encoded fimbrial structures known as 
colonization factors (CFs), have been central to all efforts to develop an ETEC vaccine, including 
those currently in advanced stages of clinical development [7,20–23,50]. These fimbriae, which are 
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restricted to the ETEC pathotype, are thought to be critical for colonization of the small intestine where 
toxin delivery is presumed to occur. Indeed, in experimental animal models of toxin delivery, 
antibodies against CFs have been shown to act synergistically when combined with antibodies  
against LT [51]. 
However, CF-based vaccines have faced a number of obstacles since these structures were 
identified [52] soon after the discovery of enterotoxigenic Escherichia coli in the early 1970s [53,54]. 
First, since the initial identification of CFA/I there have been more than 25 unique CFs identified in 
the global collection of ETEC to date, and ongoing DNA sequencing projects [55] suggest that  
new antigens will continue to be identified. This antigenic heterogeneity and lack of appreciable  
cross-protection have been addressed by multi-valent approaches to incorporate the most prevalent 
CFs [12] in candidate vaccines. Alternatively, elegant descriptions of CF biogenesis and structure  
have culminated in potential tip adhesin-based vaccines that do protect against diarrheal illness in  
an animal challenge model of ETEC infection. Many strains, as many as half of all strains in some 
series, however, lack any of the recognized CFs described thus far [31]. 
Additional data also suggest that these antigens may not alone be sufficient to stimulate the 
sustained robust protective responses that will likely be required of an ETEC vaccine. Epidemiologic 
studies of natural ETEC infections have differed with respect to whether CF immune responses 
correlate with protection against subsequent clinical illness in young children [24,56,57], the key target 
population for an ETEC vaccine. Likewise, recent studies of a live-attenuated vaccine currently in 
clinical development yielded suboptimal protection in a human volunteer challenge model despite 
robust anti-CF and anti-LT-B responses [21]. Collectively, these data suggest that our understanding of 
ETEC toxin delivery is presently incomplete and that additional effort may be required to optimize 
approaches to neutralize these critical effector molecules. 
3.4. Identification of Novel Antigens Involved in Toxin Delivery 
The challenges facing toxoid/CF-based approaches outlined above have stimulated a renewed 
interest in ETEC pathogenesis and fostered the identification of additional molecules that could be of 
importance for inclusion as subunits in a recombinant multivalent approach or targeted as part of  
a live-attenuated vaccine strategy. Outlined below (summarized in Table 1) are some more recently 
identified antigens that appear to participate in toxin delivery.  
3.4.1. EtpA Two-Partner Secretion Adhesin 
Interestingly, early enthusiasm for CFs as target for vaccine development arose from studies of  
a plasmid-cured strain of the prototypical ETEC isolate, H10407. While this strain, originally isolated 
from an adult with cholera-like diarrhea in Bangladesh, typically causes severe diarrhea in healthy 
human volunteers, recipients challenged with H10407-P, cured of a large virulence plasmid encoding 
CFA/I fimbriae, were virtually asymptomatic [58,59]. However, following transposon mutagenesis 
experiments [60] and subsequently DNA sequencing of the complete H10407 genome [61], we now 
understand that this particular plasmid encodes a number of additional virulence factors including  
ST-H, and a two-partner secretion system [60]. The ETEC “two-partner” system is actually comprised 
of three genes, etpB, an outer membrane protein responsible for transport of a secreted adhesin 
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encoded by the etpA gene, and etpC, a putative glycosyl transferase. Similar to other TPS  
systems described in Haemophilus influenza [62], efficient secretion and stability of EtpA requires  
the activity of EtpC. 
EtpA is in the same family of proteins as filamentous hemagglutinin (FHA), a component of 
modern acellular pertussis vaccines. Recognition of this similarity to a known protective antigen 
stimulated initial interest in further molecular characterization of EtpA following its identification in 
ETEC H10407. Like FHA, EtpA acts as an extracellular adhesin. EtpA acts in a unique fashion by 
bridging the ends of the long (10 µm) peritrichous flagella of ETEC with one or more host cell  
surface receptors [63]. Similar to the shorter CFs (~1 µm), EtpA-based adhesin interactions are also 
required for optimal delivery of heat-labile toxin as etpA isogenic mutants, or strains expressing  
EtpA with point mutations that render it incapable of interaction with flagellin (the major subunit of 
flagella), are demonstrably deficient in adhesion and delivery of LT to target epithelial cells [63]. 
Likewise antibodies against EtpA appear to act in concert with antibodies against either the A or B 
subunit of LT in preventing effective bacterial delivery of this toxin to epithelial cells in vitro [16]. 
Therefore, similar to the acellular pertussis vaccine approach [64], an ETEC subunit vaccine could 
combine multiple adhesins with a toxoid. 
3.4.2. Type 1 Fimbriae 
While much of ETEC vaccine development effort has focused on the plasmid-encoded CFs,  
ETEC are also known to produce other chromosomally-encoded fimbriae known as type 1 fimbriae 
(T1F) [65,66]. Similar mechanisms are involved in the biogenesis of the CFs and T1F as each involves 
a molecular chaperone and an outer membrane usher in final assembly of the pilus structures.  
In contrast to the antigenic heterogeneity exhibited by the CFs however, the T1F are highly conserved 
with minor variations in the tip adhesin molecule FimH that may select for binding to specific sugar 
residues on different epithelial surfaces. Early parental vaccination studies with preparations of type 1 
fimbriae (referred to as somatic fimbriae) did not afford significant protection in human volunteers 
challenged with the prototypical ETEC strain H10407 [67]. 
Interestingly however, recent transcriptome studies of ETEC [13] demonstrate that genes  
encoding T1F undergo significant modulation upon contact with target epithelial cells, a finding  
that suggests that these structures could be playing a role in bacterial adhesion. Indeed, emerging 
studies [14] suggest that mutants lacking either the major pilus subunit (FimA), or the tip adhesin 
(FimH) molecule are deficient in adhesion to target epithelial cells, and are less efficient than wild type 
bacteria in their delivery of heat-labile toxin. 
3.4.3. Flagellin 
The majority of human strains of ETEC are motile and can be serotyped with H antisera [68]. 
Motility appears to be an absolute requirement for effective delivery of heat-labile toxin to the epithelial 
surface [15]. Flagellin (FliC) is the major protein subunit of flagella, with an estimated 20,000 molecules 
per flagellum; therefore FliC is by far the most abundant protein secreted by ETEC, and is recognized 
during the course of infection [69]. Each FliC molecule consists of a central variable region that 
accounts for H-specific serotyping, flanked by two highly conserved alpha helical regions, which 
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promote interactions between subunits. Because ETEC encompass many H-serotypes, these antigens 
have been dismissed as potential vaccine candidates [68]. Nevertheless, antibodies against conserved 
regions of flagellin appear to protect against ETEC colonization in vivo [70] and impair bacterial 
adhesion in vitro, virulence features that are thought to be important prerequisites for toxin delivery. 
3.4.4. Secreted Mucin-Degrading Enzymes 
EatA. The eatA gene, also discovered [71] on the large H10407 virulence plasmid, encodes a serine 
protease autotransporter protein. The 110 kDa secreted passenger domain of EatA (EatAp) acts in part 
to limit EtpA-mediated adhesion, and prevent these organisms from becoming too sticky. Somewhat 
counter-intuitively, eatA mutants are retarded in their ability to deliver LT, and antibodies directed 
against the passenger domain impair delivery of LT [17]. However, homologues of EatA are also 
present in other enteric pathogens, including Shigella flexneri [72], that do not make EtpA, suggesting 
that EatA molecules have another function. Indeed, EatAp has recently been shown to cleave MUC2, 
the major mucin secreted by goblet cells lining the lumen of the intestine [73]. MUC2 normally  
serves as a major barrier to pathogen interaction with the epithelial surface. In theory, EatA and other 
mucin-degrading enzymes may effectively eliminate this obstacle to promote efficient delivery of LT. 
Interestingly, vaccination with the passenger domain EatA [18] also resulted in reduced colonization of 
the small intestine suggesting that this molecule is involved in optimal toxin delivery by a number of 
mechanisms, and that it also represents a viable vaccine candidate. 
YghJ, an antigen initially discovered by reverse vaccinology approaches with extraintestinal 
pathogenic E. coli [74], is secreted by the same type II secretion system that is responsible for export 
of the heat-labile toxin from ETEC. Recent studies have demonstrated that YghJ is recognized by 
convalescent antibody following ETEC infection [69]. YghJ belongs to a larger family of secreted 
metalloproteases capable of degrading intestinal mucins [18]. YghJ accelerates delivery of LT both  
in vitro and in vivo, and antibodies directed at YghJ impair effective toxin delivery suggesting that  
this highly conserved antigen common to most ETEC strains examined to date could be a valuable 
target for vaccine development along with pathotype-specific mucin-degrading proteins like EatA. 
4. Antigen Conservation 
One potential impediment to effective ETEC vaccine development is the underlying plasticity of  
E. coli genomes in general [75]. As noted above, this genomic plasticity has complicated traditional  
CF-based approaches to ETEC vaccines and necessitated incorporation of multiple CFs to achieve broad 
coverage of prevailing ETEC strains circulating in a given geographic area. While no completely 
conserved virulence molecule specific to the ETEC pathotype has been described to date, emerging data do 
suggest that EtpA and EatA may be more highly conserved than the classical vaccine targets and are 
present in as many as 70% of strains described to date [76,77]. The chromosomally-encoded features 
common to many E. coli, such as YghJ and the T1F tend to be more highly conserved. The degree to which 
these can be targeted without impacting commensal strains of E. coli has not been determined. 




The enterotoxigenic Escherichia coli continue to present a formidable challenge to attempts to 
develop a broadly protective vaccine. However, ETEC vaccines to date have focused on a relatively 
small subset of antigens that are not sufficiently conserved or do not alone offer sufficient protective 
efficacy to provide broad-based protection from severe diarrhea caused by ETEC. An improved 
understanding of the molecular events involved in ETEC interactions with the intestinal epithelium 
that are required for efficient delivery of its enterotoxins has provided additional targets for 
interdiction that can complement existing strategies as well as emerging toxoid-based approaches to 
toxin neutralization. These novel targets and an abundance of genomic, and immuno-proteomic data on 
the horizon should inform a rational approach to designing next generation broadly protective  
ETEC vaccines. 
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